| Literature DB >> 27700049 |
S Michael Owens1, Gerald T Pollard2, James L Howard2, Timothy R Fennell3, Rodney W Snyder3, F Ivy Carroll3.
Abstract
JDTic is a potent and selective κ-opioid receptor (KOR) antagonist that reverses U50,488-induced diuresis in rats. It partitions into brain with a duration of action lasting for weeks. In a search for KOR antagonists that do not accumulate in the brain, we compared single doses of five methylated JDTic analogs (RTI-97, -194, -212, -240, and -241) for reversal of U50,488 diuresis and pharmacokinetic (PK) properties. All six compounds showed potent and selective KOR antagonism in a [35S]GTPγS binding assay. Plasma half-lives ranged from 24 to 41 h and brain half-lives from 24 to 76 h. JDTic and RTI-194 showed increasing brain to plasma ratios over time, indicating increasing partitioning into brain and a longer duration of action for reversal of diuresis than did RTI-97. RTI-240 did not show significant brain accumulation. RTI-212 showed no substantive difference between brain and plasma levels and was inactive against diuresis. RTI-241, with a lower brain to plasma ratio than JDTic and RTI-194, formed JDTic as a metabolite, which still reduced diuresis after 9 weeks. The fact that the duration of action was correlated with the brain to blood plasma ratios and area under the concentration-time curves suggests that PK properties could help to predict safety and acceptable duration of action for KOR antagonists.Entities:
Keywords: JDTic; brain; diuresis; pharmacokinetics; prodrug; rat; κ-opioid receptor antagonist
Mesh:
Substances:
Year: 2016 PMID: 27700049 PMCID: PMC6532972 DOI: 10.1021/acschemneuro.6b00249
Source DB: PubMed Journal: ACS Chem Neurosci ISSN: 1948-7193 Impact factor: 4.418